Trial · NCT02967458
Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study
NCT02967458, Phase 2, Completed, Thomas Jefferson University; results first posted 2019-05-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study. Trials, record NCT02967458. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02967458
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study
- NCT number
- NCT02967458
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 55 participants, actual
- Lead sponsor
- Thomas Jefferson University
- Conditions
- Prostatic Neoplasm
- Interventions
- Perflutren Lipid Microsphere Intravenous Suspension
- First posted
- 2016-11-18
- Last updated
- 2025-04-30
- Results first posted
- 2019-05-21
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Subjects Whose Prostate Cancer Was Detected With Subharmonic Imaging | One week from baseline | The initial phase of the trial will develop and test subharmonic imaging to demonstrate enhanced visualization of prostate vascularity in all study participants. We will report the percentage of study subjects in whom visualization of prostate vascularity is increased with subharmonic imaging. |
| Primary | Percentage of Biopsy Cores in Which Prostate Cancer Was Detected Using Subharmonic Imaging | One week from baseline | Study subjects will be scanned with subharmonic imaging during infusion of the microbubble contrast agent. Imaging results will be compared to pathology on prostate biopsy. |
| Primary | Percentage of Subjects With Previously Unidentified Prostate Cancer Using Magnetic Resonance Imaging | One week from baseline | Study subjects will be scanned with subharmonic imaging during infusion of the microbubble contrast agent. Imaging results will be compared to pathology on prostate biopsy. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Subjects Whose Prostate Cancer Was Detected With Subharmonic Imaging | One week from baseline | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Percentage of Biopsy Cores in Which Prostate Cancer Was Detected Using Subharmonic Imaging | One week from baseline | percentage of biopsy cores | NUMBER | |
| PRIMARY | Percentage of Subjects With Previously Unidentified Prostate Cancer Using Magnetic Resonance Imaging | One week from baseline | Thirty one subjects of the total 55 had prior negative MRI or negative MRI guided biopsy | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Subjects Whose Prostate Cancer Was Detected With Subharmonic Imaging | 1Prostate Biopsy Patients | 24 | Participants | ||
| Percentage of Biopsy Cores in Which Prostate Cancer Was Detected Using Subharmonic Imaging | Prostate Biopsy Patients | 8.33 | percentage of biopsy cores | ||
| Percentage of Subjects With Previously Unidentified Prostate Cancer Using Magnetic Resonance Imaging | Prostate Biopsy Patients | 9 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Prostate Biopsy Patients | 55 | |
| Overall Study | COMPLETED | Prostate Biopsy Patients | 55 | |
| Overall Study | NOT COMPLETED | Prostate Biopsy Patients | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hives | Skin and subcutaneous tissue disorders | Prostate Biopsy Patients | 1 | 55 | 1 |
| other | Throat Tightness | General disorders | Prostate Biopsy Patients | 1 | 55 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Prostate Biopsy Patients | 0 | 55 |
| Total, other adverse events | Prostate Biopsy Patients | 2 | 55 |
| Total, serious adverse events | Prostate Biopsy Patients | 0 | 55 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R21CA202214 | Detection of High Grade Prostate Cancer with Subharmonic Ultrasound Imaging | HALPERN, ETHAN J; FORSBERG, FLEMMING | THOMAS JEFFERSON UNIVERSITY | NATIONAL CANCER INSTITUTE | 2016 to 2017 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02967458
GET https://conductscience.org/api/trials/v1/NCT02967458/registered